Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

First Patient Dosed in a Phase 1 Trial with Neoantigen Cancer Vaccine

americanpharmaceuticalreviewDecember 12, 2019

Tag: neoantigen , Nouscom , NOUS-209

PharmaSources Customer Service